111
Views
5
CrossRef citations to date
0
Altmetric
Articles

Cyclin D1 and PSA act as good prognostic and clinicopathological indicators for breast cancer

&

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Masoud Najafi, Shima Tavakol, Ali Zarrabi & Milad Ashrafizadeh. (2022) Dual role of quercetin in enhancing the efficacy of cisplatin in chemotherapy and protection against its side effects: a review. Archives of Physiology and Biochemistry 128:6, pages 1438-1452.
Read now

Articles from other publishers (3)

Andreia Fabiana do Vale Franco, Andrea Cristina Moraes Malinverni & Angela Flavia Logullo Waitzberg. (2023) Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab. Pathology - Research and Practice 252, pages 154917.
Crossref
IbrahimYaseen Hachim, MahmoodYaseen Hachim, VanessaMichel López-Ozuna & RajiH M Al-Hadithi. (2022) Expression of tissue PSA in breast cancer is associated with less aggressive disease and lower chance of tumor relapse. Advances in Biomedical and Health Sciences 1:3, pages 121.
Crossref
Yijun Liu, Qingluan Liu, Zhicheng Wang, Meilin Chen, Yi Chen, Xiayu Li, Donghai Huang, Songqing Fan, Wei Xiong, Guiyuan Li & Wenling Zhang. (2020) Upregulation of cyclin D1 can act as an independent prognostic marker for longer survival time in human nasopharyngeal carcinoma. Journal of Clinical Laboratory Analysis 34:8.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.